Stoke Therapeutics Financial Statements
NASDAQ: STOKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Stoke Therapeutics revenue and earnings
In fiscal 2025, Stoke Therapeutics generated $184.4 million in revenue, up 404.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Stoke Therapeutics reported a net loss of $6.9 million, compared with a loss of $89.0 million a year earlier. Operating margin was -11.2%.
Diluted earnings per share came in at -$0.12.
Summary generated from market data by MetaCap's automated system. Methodology
Stoke Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 184.42M | 36.55M | 8.78M | 12.40M | — | — | — | — |
| Revenue growth (YoY) | +404.50% | +316.34% | -29.22% | — | — | — | — | — |
| Operating Expenses | 205.01M | 137.93M | 123.55M | 116.76M | 86.06M | 53.04M | 35.68M | 12.78M |
| Research & Development | 137.92M | 89.13M | 82.23M | 77.84M | 54.17M | 32.20M | 23.76M | 8.37M |
| Selling, General & Admin | 67.09M | 48.79M | — | — | — | — | — | — |
| Operating Income | -20.59M | -101.37M | -114.77M | -104.36M | -86.06M | -53.04M | -35.68M | -12.78M |
| Interest Expense | 9.00K | 26.00K | 49.00K | — | — | — | — | — |
| Other Income (Expense) | 13.71M | 12.39M | 10.07M | 3.29M | 260.00K | 801.00K | 3.35M | 260.00K |
| Income Tax | 0 | — | — | — | — | — | — | — |
| Net Income | -6.88M | -88.98M | -104.70M | -101.07M | -85.81M | -52.24M | -32.33M | -12.52M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | -1.56 | -1.80 | -17.65 |
| EPS (Diluted) | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | -1.56 | -1.80 | -17.65 |
| Shares Outstanding (Basic) | 59.22M | 54.01M | 43.99M | 38.90M | 36.74M | 33.49M | 17.97M | 709.34K |
| Shares Outstanding (Diluted) | 59.22M | 54.01M | 43.99M | 38.90M | 36.74M | 33.49M | 17.97M | 709.34K |
| EBITDA | -18.82M | -99.19M | -112.30M | -102.81M | -85.09M | -52.16M | -35.23M | -12.57M |
| Operating Margin | -11.16% | -277.31% | -1307.21% | -841.24% | — | — | — | — |
| Net Margin | -3.73% | -243.42% | -1192.47% | -814.73% | — | — | — | — |
This table shows 8 annual periods of Stoke Therapeutics's income statement, from FY 2025 back to FY 2018, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow STOK's reporting calendar. What is a income statement?